MKNK1
MOLECULAR TARGETMAPK interacting serine/threonine kinase 1
MKNK1 (MAPK interacting serine/threonine kinase 1) is targeted by 27 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting MKNK1
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | gefitinib | 5.67 | 290 |
| 2 | erlotinib | 5.55 | 256 |
| 3 | foretinib | 4.34 | 76 |
| 4 | vandetanib | 4.30 | 73 |
| 5 | doramapimod | 4.06 | 57 |
| 6 | brigatinib | 3.81 | 44 |
| 7 | canertinib | 3.53 | 33 |
| 8 | bms 387032 | 3.47 | 31 |
| 9 | fedratinib | 3.40 | 29 |
| 10 | linifanib | 3.33 | 27 |
| 11 | hispidulin | 3.33 | 27 |
| 12 | dorsomorphin | 3.14 | 22 |
| 13 | lestaurtinib | 3.04 | 20 |
| 14 | ruboxistaurin | 2.94 | 18 |
| 15 | r 406 | 2.83 | 16 |
| 16 | ast 487 | 2.56 | 12 |
| 17 | merestinib | 2.48 | 11 |
| 18 | su 014813 | 2.20 | 8 |
| 19 | tg100 115 | 2.08 | 7 |
| 20 | tomivosertib | 2.08 | 7 |
| 21 | tinodasertib | 1.95 | 6 |
| 22 | aigialomycin d | 1.79 | 5 |
| 23 | Sorafenib | 1.39 | 3 |
| 24 | Luteolin 5,7,3',4'-tetrahydroxy-flavone, | 0.69 | 1 |
| 25 | Afatinib | 0.69 | 1 |
| 26 | hydroxyfasudil [Supplementary Concept] | 0.69 | 1 |
| 27 | tyrphostin ag 1478 | 0.69 | 1 |
About MKNK1 as a Drug Target
MKNK1 (MAPK interacting serine/threonine kinase 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 27 compounds with documented MKNK1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
MKNK1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.